GEN Edge - Latest

Latest

Drug Discovery

The Upregulation Revolution: CAMP4’s Climb to Reach Untouched Diseases by Dialing Up Gene Expression

Artificial Intelligence

Growth Signals: Sema4 Navigates Precision Medicine with $500M SPAC

Blood Disorders

Love is on the Air: The March to Cure Sickle Cell Disease

GEN Edge

“GEN Edge Live”: Analyzing the Latest Milestones in Genome Editing

Drug Discovery

Breaker of Chains: Karuna Therapeutics Challenges Antipsychotic Drug Barrier

Cancer

Going BIG: Daphne Zohar on “Close to the Edge”

Antibodies

Heart of the Deal: Prothena Executives on the $1.2B Sale of ATTR Amyloidosis Candidate to Novo Nordisk

Artificial Intelligence

By Decoding Patient Drug Responses, Scipher Medicine Tackles Wasteful Healthcare Spending

GEN Edge

Close to the Edge: Regeneron’s George Yancopoulos and Aris Baras Discuss Company, COVID-19

Companies

Introducing “Close to the Edge”: A Zoom Conversation with PacBio CEO Christian Henry

Coronavirus

The COVID-19 Pandemic: Lessons for the Future

Cell Therapy

ViaCyte’s Sweet Three-Pronged Attack against Type 1 Diabetes

Cancer

Second Path: Dendreon Seeks Growth beyond Provenge

Anal Cancer

Cellares’ Automation Route for Cancer Cell Therapy

GEN Edge

Tissue Growth: Axogen’s Biologic Transition Leads to Expansion

Cancer

Regional Power: Japan’s Kyowa Kirin Builds on U.S. Growth

GEN Edge

Rothberg Returns: Quantum-Si Aims to Turn Proteomics Digital

Drug Discovery

venBio Writes New Chapter with $550M Fourth Fund

Biomarkers

We Have Lift Off: Codiak BioSciences Bears Down with Exosomes as a Therapeutic Modality

Drug Discovery

Designer Genes: Synlogic Is Crafting Living Therapeutics Programmed to Treat Disease

Drug Discovery

One in a Million: Homology Medicines Targets New Approach for Rare Genetic Diseases

Cell Line Development

Off Message: Dyadic Fights COVID-19 with a Fungus

Drug Discovery

Complementary Challenge: Apellis Throws Down the Gauntlet

Drug Discovery

Heavyweight Division: Arvinas Paves the Way for Therapeutics That Degrade Disease-Related Proteins

AGTC

AGTC Proves a Durable Competitor in Gene Therapy for X-Linked Retinitis Pigmentosa

Drug Discovery

Community Building: Interline Translating Protein Interactions into Treatments

GEN Edge

VAST Sees a Big Opportunity in Life Sciences

AAV (Adeno-associated virus)

Mountain Climbing: Dyno Fights AAV Vector Immune Response with $100M

Antibodies

AbCellera, Lilly Advance Next-Generation Antibody vs. COVID-19

Coronavirus

From Pandemic to Pipeline: What’s Next for Moderna?